We Claim:

1. Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein a therapeutically effective amount of the tofacitinib or the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2.

2. Use of tofacitinib or a pharmaceutically acceptable salt thereofin the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 5 mgs of tofacitinib BID or an equivalent amount of tofacitinib in the form of the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2.

3. Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID or an equivalent amount of tofacitinib in the form of the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2.

4. Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 11 mgs of tofacitinib QD or an equivalent amount of tofacitinib in the form of the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2.

5. Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein a therapeutically effective amount of tofacitinib, or an equivalent amount of tofacitinib in the form of the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2 to reduce IL-6 levels by at least 20%.

6. Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 2.5-15 mgs of tofacitinib, or an equivalent amount of tofacitinib in the form of the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV to reduce IL-6 levels by at least 20%.

7. Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID, or an equivalent amount of tofacitinib in the form of the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV to reduce IL-6 levels by at least 20%.

8. Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID, or an equivalent amount of tofacitinib in the form of the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV to reduce IL-6 levels by at least 50%.

9. Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID, or an equivalent amount of tofacitinib in the form of the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV to reduce IL-6 levels by at least 75%.

10. Use of tofacitinib or a pharmaceutically acceptable salt thereofin the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID, or an equivalent

amount of tofacitinib in the form of the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV to reduce IL-6 and IL-8 levels each by at least 35%.

11. Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID, or an equivalent amount of tofacitinib in the form of the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV to reduce IL-6, IL-8, and TNFα levels each by at least 35%.

12. Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID or an equivalent amount of tofacitinib in the form of the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV-2 to reduce IL-6, IFNα, IFNβ, and TNFα levelseach by at least 35%.

13. Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID, or an equivalent amount of tofacitinib in the form of the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV-2 to reduce IFNγ, IL-6, IL-15, IL-21, and IL-27 levels each by at least 20%.

14. Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID, or an equivalent amount of tofacitinib in the form of the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV-2 to reduce IFNα, IFNγ, IL-2, IL4, IL-6, IL-7, IL-10, IL-12, IL13, IL-15, and IL-23 levels each by at least 20%.

15. Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 400 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide QD or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide in the form of the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2.

16. Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 200 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide Q6H or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide in the form of the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2.

17. Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein a therapeutically effective amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide in the form of the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2 to reduce IL-6 levels by at least 75%.

18. Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 100-800 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide in the form of the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2 to reduce IL-6 levels by at least 75%.

19. Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 400 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide QD, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide in the form of the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV-2 to reduce IL-6 levels by at least 75%.

20. Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 200 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide Q6H, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide in the form of the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2 to reduce IL-6 levels by at least 75%.

21. Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 400 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide QD, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide in the form of the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV-2 to reduce IL-6 IL-1, and TNFα levels each by at least 20%.

22. Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 200 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide Q6H, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide in the form of the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2 to reduce IL-6 IL-1, and TNFα levels each by at least 20%.

23. Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 400 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide QD, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide in the form of the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV-2 to reduce IL-6 IL-1, TNFα, IFNα, and IFNy levels each by at least 20%.

24. Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 200 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide Q6H, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide in the form of the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2 to reduce IL-6 IL-1, TNFα, IFNα, and IFNy levels each by at least 20%.

25. Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 400 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide QD, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide in the form of the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV-2 to reduce IL-6 IL-1, TNFα, IFNα, IFNy, and CXCL8 levels each by at least 20%.

26. Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 200 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide Q6H, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide in the form of the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2 to reduce IL-6 IL-1, TNFα, IFNα, IFNy, and CXCL8 levels each by at least 20%.

27. Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 400 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide QD, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide in the form of the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV-2 to reduce CRP levels by at least 50% and IL-6 IL-1, TNFα, IFNα, IFNy, and CXCL8 levels each by at least 20%.

28. Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 200 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide Q6H, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide in the form of the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2 to reduce CRP levels by at least 50% and IL-6 IL-1, TNFα, IFNα, IFNy, and CXCL8 levels each by at least 20%.